Profile data is unavailable for this security.
About the company
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.
- Revenue in EUR (TTM)37.55bn
- Net income in EUR5.81bn
- LocationSanofi SA54 rue la BoetiePARIS 75008FranceFRA
- Phone+33 153774000
- Fax+33 153774463
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|SAN:PAR since |
|Kadmon Holdings Inc||Announced||08 Sep 2021||08 Sep 2021Announced||-6.21%||1.76bn|
|Translate Bio Inc||Deal completed||03 Aug 2021||03 Aug 2021Deal completed||-5.99%||3.04bn|
|Tidal Therapeutics Inc||Deal completed||09 Apr 2021||09 Apr 2021Deal completed||-3.73%||470.00m|
|Kymab Group Ltd||Deal completed||11 Jan 2021||11 Jan 2021Deal completed||3.50%||1.45bn|
|Kiadis Pharma NV||Deal completed||02 Nov 2020||02 Nov 2020Deal completed||5.40%||254.17m|